Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

Completed

Phase 2/3 Results N/A

Eligibility Criteria

Inclusion Criteria

- >18 years of age
- Anterior-circulation ischemic stroke: All patients had symptoms of focal neurological deficits and simultaneous radiological evidence (magnetic resonance imaging, MRI) of an ischemic brain lesion
- measurable neurological deficit (NIHSS > 5)
- interval between symptom onset and admission more than 4.5 hours and less than 48 hours. That is, all patients we recruited were beyond the 4.5 hours of symptom onset and, therefore, past the accepted time-window for thrombolytic therapy

Exclusion Criteria

- hemorrhagic stroke and severe hemorrhage in other organs
- other diseases of the central nervous system (CNS)
- diabetes mellitus
- tumor or hematological systemic diseases
- any infection before acute ischemic stroke
- concomitant use of antineoplastic or immune modulating therapies
- contraindication to MRI